15 research outputs found
Colorectal tumors require NUAK1 for protection from oxidative stress
The authors wish to thank the staff of the CRUK Beatson Institute Biological Services Unit for animal husbandry and assistance with in vivo experiments; the staff of the CRUK BI Histology core facility and William Clark of the NGS core facility; David McGarry, Rene Jackstadt, Jiska Van der Reest, Justin Bower and Heather McKinnon for many helpful discussions, and countless colleagues at the CRUK BI and Glasgow Institute of Cancer Sciences for support; Prem Premsrirut & Mirimus Inc. for design and generation of dox-inducible Nuak1 shRNA expressing mice Nathanael Gray for initial provision of NUAK1 inhibitors. Funding was provided by the University of Glasgow and the CRUK Beaton Institute. J.P. was supported by European Commission Marie Curie actions C.I.G. 618448 âSERPLUCâ to D.J.M.; N.M. was supported through Worldwide Cancer (formerly AICR) grant 15-0279 to O.J.S. & D.J.M.; B.K. was funded through EC Marie Curie actions mobility award 705190 âNuSiCCâ; T.M. was funded through British Lung Foundation grant APHD13-5. The laboratories of S.R.Z. (A12935), O.J.S. (A21139) and M.D. (A17096) are funded by Cancer Research UK. O.J.S. was additionally supported by European Research Council grant 311301 âColoCanâ.Peer reviewedPostprin
Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal
Tuberous sclerosis complex (TSC) is caused by inactivating variants in TSC1 and TSC2. Somatic mosaicism, as well as the size and complexity of the TSC1 and TSC2 loci, makes variant identification challenging. Indeed, in some individuals with a clinical diagnosis of TSC, diagnostic testing fails to identify an inactivating variant. To improve TSC1 and TSC2 variant detection, we screened the TSC1 and TSC2 genomic regions using targeted HaloPlex custom capture and next-generation sequencing (NGS) in genomic DNA isolated from peripheral blood of individuals with definite, possible or suspected TSC in whom no disease-associated variant had been identified by previous diagnostic genetic testing. We obtained >95% target region coverage at a read depth of 20 and >50% coverage at a read depth of 300 and identified inactivating TSC1 or TSC2 variants in 83/155 individuals (54%); 65/113 (58%) with clinically definite TSC and 18/42 (43%) with possible or suspected TSC. These included 19 individuals with deep intronic variants and 54 likely cases of mosaicism (variant allele frequency 1-28%; median 7%). In 13 cases (8%), we identified a variant of uncertain significance (VUS). Targeted genomic NGS of TSC1 and TSC2 increases the yield of inactivating variants found in individuals with suspected TSC.</p
Genomic investigations of unexplained acute hepatitis in children
Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis in children have been reported worldwide, including 278 cases in the UK1. Here we report an investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator participants, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in the liver, blood, plasma or stool from 27 of 28 cases. We found low levels of adenovirus (HAdV) and human herpesvirus 6B (HHV-6B) in 23 of 31 and 16 of 23, respectively, of the cases tested. By contrast, AAV2 was infrequently detected and at low titre in the blood or the liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded the emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T cells and B lineage cells. Proteomic comparison of liver tissue from cases and healthy controls identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV-mediated and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and, in severe cases, HHV-6B may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children
Quantico and Intersectionality
Quantico aired September 2015 and has garnered a steady following of viewers, curious to see how the show will progress. The show follows Alex Parrish (Priyanka Chopra), a half Indian and half Caucasian, recruit for the FBI being framed for a terrorist attack in New York City. Along with Parrish there are about a half dozen other characters portrayed in a very intersectional way through their race, gender, or status on the show. Chopraâs character is particularly fascinating because she is the lead of the show but as a half Indian she is not portrayed as other Indians are in the media. In various scenes Parrish mentions some of the stereotypes or perceptions that she is faced with because of her identities and roles. I will explore how the concept of the mythical norm is portrayed on the show Quantico along with the idea of the traffic intersection as explained by Kimberle Crenshaw. Both are clearly visible throughout the show not just with the lead character, Alex Parrish, but also other leads. I will evaluate how the basement theory (also by Crenshaw but explained by Anna Carastathis) relates to the lead characters of Quantico, particularly Alex Parrish, and explore how the basement theory is also shown in various ways on the show. Finally I will review the benefits of having a show like Quantico that portrays more diversity and backgrounds for a greater variety and range of characters
Gender, Race, Ethnicity, and Media
Please click the links below to view more information about each presentation.
âThe Resting âBitchâ Face: Exploring the Intersection of African American Women, Race, Class, Sexuality, Gender and Reality TVâ
Felecia C. Harris, University of North Carolina at Charlotte
âThe MisEducation of The Mistress: Black Women in the Mediaâ
Andrea Dobynes, University of Alabama - Tuscaloosa
âEmpowerment or Disempowerment? The Portrayal of Black Women in Tyler Perryâs Films
Helyne Frederick, Winthrop University; Kishonna Gray, Eastern Kentucky University; Amber Gadsden, Winthrop University; and Myesha Mickens, Winthrop University
âQuantico and Intersectionalityâ
Meera J. Raja, Towson Universit
Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic ÎČ-cell function
RNA interference using c-Myc-conjugated nanoparticles suppresses breast and colorectal cancer models
In this article, we report the development and preclinical validation of combinatorial therapy for treatment of cancers using RNA interference (RNAi). RNAi technology is an attractive approach to silence genes responsible for disease onset and progression. Currently, the critical challenge facing the clinical success of RNAi technology is in the difficulty of delivery of RNAi inducers, due to low transfection efficiency, difficulties of integration into host DNA and unstable expression. Using the macromolecule polyglycidal methacrylate (PGMA) as a platform to graft multiple polyethyleneimine (PEI) chains, we demonstrate effective delivery of small oligos (anti-miRs and mimics) and larger DNAs (encoding shRNAs) in a wide variety of cancer cell lines by successful silencing/activation of their respective target genes. Furthermore, the effectiveness of this therapy was validated for in vivo tumor suppression using two transgenic mouse models; first, tumor growth arrest and increased animal survival was seen in mice bearing Brca2/p53-mutant mammary tumors following daily intratumoral treatment with nanoparticles conjugated to c-Myc shRNA. Second, oral delivery of the conjugate to an Apc-deficient crypt progenitor colon cancer model increased animal survival and returned intestinal tissue to a nonâwnt-deregulated state. This study demonstrates, through careful design of nonviral nanoparticles and appropriate selection of therapeutic gene targets, that RNAi technology can be made an affordable and amenable therapy for cancer. Mol Cancer Ther; 14(5); 1259â69. ©2015 AACR
Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve <em>In Vitro</em> and <em>In Vivo</em>
<div><p>Advances in cancer therapy have increased the rate of survival of young cancer patients; however, female lymphoma patients frequently face a temporary or permanent loss of fertility when treated with traditional cytotoxic agents. The potential loss of fertility is an important concern that can influence treatment decisions for many premenopausal cancer patients. The negative effect of chemotherapeutic agents and treatment protocols to patientsâ fertilityâreferred to as fertotoxicityâare thus an increasingly important cancer survivorship issue. We have developed a novel nanoscale formulation of arsenic trioxide, a potent drug for treatment of hematological malignancies, and demonstrate that it has significantly better activity in a murine lymphoma model than the free drug. In parallel, we have developed a novel <i>in vitro</i> assay of ovarian follicle function that predicts <i>in vivo</i> ovarian toxicity of therapeutic agents. Our results reveal that the nanotherapeutic agent is not only more active against lymphoma, but is fertoprotective, i.e., it is much less deleterious to ovarian function than the parent drug. Thus, our <i>in vitro</i> assay allows rapid evaluation of both established and experimental anticancer drugs on ovarian reserve and can inform the selection of efficacious and fertility-sparing treatment regimens for reproductive-age women diagnosed with cancer.</p> </div
Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- andMUTYH-associated Polyposis
Purpose: Duodenal polyposis and cancer are important causes of morbidity and mortality in familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). This study aimed to comprehensively characterize somatic genetic changes in FAP and MAP duodenal adenomas to better understand duodenal tumorigenesis in these disorders. Experimental Design: Sixty-nine adenomas were biopsied during endoscopy in 16 FAP and 10 MAP patients with duodenal polyposis. Ten FAP and 10 MAP adenomas and matched blood DNA samples were exome sequenced, 42 further adenomas underwent targeted sequencing, and 47 were studied by array comparative genomic hybridization. Findings in FAP and MAP duodenal adenomas were compared with each other and to the reported mutational landscape in FAP and MAP colorectal adenomas. Results: MAP duodenal adenomas had significantly more protein-changing somatic mutations (P = 0.018), truncating mutations (P = 0.006), and copy number variants (P = 0.005) than FAP duodenal adenomas, even though MAP patients had lower Spigelman stage duodenal polyposis. Fifteen genes were significantly recurrently mutated. Targeted sequencing of APC, KRAS, PTCHD2, and PLCL1 identified further mutations in each of these genes in additional duodenal adenomas. In contrast to MAP and FAP colorectal adenomas, neither exome nor targeted sequencing identified WTX mutations (P = 0.0017). Conclusions: The mutational landscapes in FAP and MAP duodenal adenomas overlapped with, but had significant differences to those reported in colorectal adenomas. The significantly higher burden of somatic mutations in MAP than FAP duodenal adenomas despite lower Spigelman stage disease could increase cancer risk in the context of apparently less severe benign disease
NB(Ni,As) inhibits mantle cell lymphoma growth.
<p>18 days after inoculation with Z138C lymphoma cells, Rag2M mice were randomized and treated with weekly injections of NB(NaCl), As<sub>2</sub>O<sub>3</sub> (4, 6, or 8 mg/kg), or NB(Ni,As) (4, 6, or 8 mg/kg). (A) Tumors treated with NB(Ni,As) were significantly smaller than those treated with NB(NaCl). **, <i>P</i>>0.01, ***, <i>P</i>>0.001. Arrows indicate treatment. (B) Weight was monitored daily during the treatment period. Injection of As<sub>2</sub>O<sub>3</sub> was acutely toxic, whereas mice injected with NB(NaCl) showed normal weight gain. Mice injected with any dose of NB(Ni,As) lost weight, though mice treated with 4 mg/kg showed the least amount of weight loss during the treatment period.</p